Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07834684

Singula Phase 0.1 Primary Care Pilot

This prospective, single-arm, observational pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care. Adult patients complete a self-report assessment before a routine primary care visit. The system uses the responses to generate a clinician-facing Companion Brief that summarizes relevant information for the treating clinician. Each Companion Brief is reviewed by the Principal Investigator before it is provided to the clinician. The study will evaluate whether the system can reliably generate and deliver the Companion Briefs, whether clinicians find the Briefs useful and acceptable, and whether patients can successfully complete and accept the pre-visit assessment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Morris Medical Office, Brentwood, New York, United States

Loading trial locations.

About this study

The Singula clinical decision support system is designed to organize information collected from a patient before a routine primary care visit into a structured Companion Brief for the treating clinician. The pre-visit assessment includes validated screening measures and structured questions addressing behavioral health symptoms and other factors relevant to the patient's clinical context. After a patient completes the assessment, an automated software pipeline processes the responses and generates a draft Companion Brief. The Principal Investigator reviews each Artificial Intelligence (AI)-generated Brief for clinical accuracy, appropriate safety language, and potential errors before it is released to the treating clinician. The treating clinician receives the reviewed Brief before the patient's routine primary care visit and retains full independent authority over clinical assessment and decision-making. The Companion Brief is informational and does not direct treatment. This Phase 0.1 pilot is intended primarily to characterize the feasibility and operational performance of this workflow in real-world primary care. The study will examine successful generation and delivery of Companion Briefs, pipeline performance, clinician feedback regarding the utility and acceptability of the Briefs, patient completion of the pre-visit assessment, and errors or other operational issues identified during the pilot. Findings from this study are intended to inform subsequent technical, operational, and clinical development of the system.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult, aged 18 years or older at the time of consent.
  • Scheduled for a routine, non-urgent primary care visit at a participating practice.
  • Able to read and understand English at a level sufficient to complete the electronic informed consent and Survey 0.1 independently.
  • Has personal-device access to complete the survey (smartphone, tablet, or computer with internet).
  • Capable of providing informed consent.

Exclusion criteria

  • Non-English-speaking, defined as inability to read English at a level sufficient to complete electronic informed consent and the survey independently.
  • Visually impaired to a degree that prevents independent reading of an electronic consent form on a personal device, without specialized assistive technology beyond standard mobile-device accessibility features.
  • Unable to read for any reason (literacy, cognitive impairment, or other).
  • Presenting with an acute psychiatric emergency or in acute crisis at the time of the scheduled visit, as identified by clinic staff during routine check-in.
  • Patient is a known minor at the time of scheduling (under 18 years).
  • Patient or clinician declines participation.

Treatment and study plan

Primary outcomes

  1. Successful Production and Delivery of the Companion Brief

    Time frame: Up to 7 days

    Proportion of enrolled patient cases for which an Artificial Intelligence (AI)-generated Companion Brief is successfully produced, reviewed by the Principal Investigator, and delivered to the treating clinician prior to the patient's scheduled visit.

  2. Clinician-Rated Overall Clinical Utility of the Companion Brief

    Time frame: Periodic feedback during active enrollment, approximately 30 to 90 days

    Clinician-rated overall clinical utility of the Companion Brief, captured on the periodic batched feedback survey using a 5-point Likert scale. Target: ≥70% of feedback batches indicating overall utility of "useful" or "very useful" across the cases covered in each batch.

Secondary outcomes

  1. Survey 0.1 Completion Rate

    Time frame: Up to 7 days

    Completion rate of Survey 0.1 among consented patient participants

  2. Pipeline End-to-End Latency

    Time frame: Up to 72 hours

    End-to-end latency from Survey 0.1 submission to availability of the generated Companion Brief in storage.

  3. Principal Investigator Corrections to Large Language Model (LLM)-Generated Reports

    Time frame: Up to 7 days

    Number and category of Principal Investigator corrections to Large Language Model (LLM)-Generated Companion Briefs, categorized as clinical accuracy, safety language, formatting, or hallucination.

  4. Number of Safety-Flag Triggers Generated by the Clinical Decision Support System

    Time frame: Up to 8 days

    Total number of safety-flag triggers generated by the clinical decision support system during the study period. Safety-flag triggers will be classified by risk level (Critical or High) for descriptive reporting.

  5. Number of Safety-Flag Triggers by Documented Disposition

    Time frame: Up to 8 days

    Number of safety-flag triggers by documented disposition category following Principal Investigator review and clinician notification.

  6. Clinician-Rated Most Useful Companion Brief Section

    Time frame: Periodic feedback during active enrollment, approximately 30 to 90 days

    Clinician identification of the most useful Companion Brief section across cases included in each feedback batch.

  7. Number of Feedback Batches With Clinician-Reported Influence on Clinical Decision-Making, Measured by the Singula Clinician Feedback Survey

    Time frame: Periodic feedback during active enrollment, approximately 30 to 90 days

    Clinician-reported influence of Companion Briefs on clinical decision-making will be assessed using the Singula Clinician Feedback Survey. For each feedback batch, clinicians will indicate whether any Companion Brief in the batch period influenced a clinical decision. The outcome will be reported as the number of feedback batches in which an influence on clinical decision-making was reported.

  8. Clinician-Reported Willingness to Continue Using the Companion Brief, Measured by the Singula Clinician Feedback Survey

    Time frame: Periodic feedback during active enrollment, approximately 30 to 90 days

    Clinician-reported willingness to continue using the Companion Brief system will be assessed using the Singula Clinician Feedback Survey. Responses will be summarized across clinician feedback collected during the study period.

  9. Patient Survey Dropout and Skip Patterns

    Time frame: Up to 7 days

    Patient-side dropout and question-skipping patterns during completion of Survey 0.1.

Study contacts

Contact information is provided by the study sponsor or research team.

Marc S Lener, MD

CONTACT

[email protected]

(240) 389-2381

Sponsors and collaborators

Lead sponsor

Singula Health, Inc.

Industry

Registry information

Official study title

Validation of an Artificial Intelligence (AI)-Powered Clinical Decision Support System for Anxiety and Depression in Primary Care Settings

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Sep 22, 2026
Registry last updated
Sep 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.